| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
RESEARCH COMMUNICATION |
a Department of Medicine, Cardiovascular Division, and Department of Pharmacology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
b Garvan Institute for Medical Research, Sydney, Australia
c Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, Maryland 20892–1008, USA
Adenosine is an important mediator of the endogenous defense against ischemia-induced injury in the heart. Adenosine can achieve cardioprotection by mediating the effect of ischemic preconditioning and by protecting against myocyte injury when it is present during the infarct-producing ischemia. A novel adenosine A3 receptor can mediate this protective function. One approach to achieve cardioprotection is to enhance myocardial sensitivity to the endogenous adenosine by increasing the number of adenosine receptors instead of administering an adenosine receptor agonist. The objective of the present study was to investigate whether genetic manipulation of the cardiac myocyte, achieved by gene transfer and overexpression of the human A3 receptor cDNA, renders the myocytes resistant to the deleterious effect of ischemia. Prolonged hypoxia with glucose deprivation, causing myocyte injury and adenosine release, was used to simulate ischemia in cultured chick embryo ventricular myocytes. During simulated ischemia, cultured myocytes with enhanced expression of the human A3 receptor and showed significantly higher ATP content, fewer cells killed, and less creatine kinase released into the medium than either control or mock-transfected myocytes. Also, increased expression of the A3 receptor caused an enhanced cardioprotective effect by the preconditioning ischemia. Overexpressing the adenosine A1 receptor also led to increased protection against ischemia-induced myocyte injury as well as an enhanced preconditioning effect. Thus, increasing the receptor level improves the myocyte sensitivity to the endogenous adenosine, which in turn causes all of the cardioprotective effects found for exogenously administered adenosine agonists. The study provides the first proof for the new concept that an increased expression of the human A3 receptor in the cardiac myocyte can be an important cardioprotective therapeutic approach.—Dougherty, C., Barucha, J., Schofield, P. E., Jacobson, K. A., Liang, B. T. Cardiac myocytes rendered ischemia resistant by expressing the human adenosine A1 or A3 receptor. FASEB J. 12, 1785–1792 (1998)
Key Words: heart • purinergic • ventricular myocyte • gene transfer
This article has been cited by other articles:
|
|
 |
|
  M. Hofer, M. Pospisil, V. Znojil, J. Hola, D. Streitova, and A. Vacek Homeostatic Action of Adenosine A3 and A1 Receptor Agonists on Proliferation of Hematopoietic Precursor Cells Experimental Biology and Medicine, July 1, 2008; 233(7): 897 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Diaz and G. J. Wilson Studying ischemic preconditioning in isolated cardiomyocyte models Cardiovasc Res, May 1, 2006; 70(2): 286 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lu, W.-J. Zang, X.-J. Yu, L.-N. Chen, C.-H. Zhang, and B. Jia Effects of ischaemia-mimetic factors on isolated rat ventricular myocytes Exp Physiol, July 1, 2005; 90(4): 497 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Jacobson, S.-K. Kim, S. Costanzi, and Z.-G. Gao PURINE RECEPTORS: GPCR STRUCTURE AND AGONIST DESIGN Mol. Interv., December 1, 2004; 4(6): 337 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Headrick, B. Hack, and K. J. Ashton Acute adenosinergic cardioprotection in ischemic-reperfused hearts Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1797 - H1818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Zhao and R. C. Kukreja Protein kinase C-{delta} mediates adenosine A3 receptor-induced delayed cardioprotection in mouse Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H434 - H441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.F Baxter Role of adenosine in delayed preconditioning of myocardium Cardiovasc Res, August 15, 2002; 55(3): 483 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Black Jr, Y. Guo, Z.-D. Ge, S. S. Murphree, S. D. Prabhu, W. K. Jones, R. Bolli, and J. A. Auchampach Gene Dosage-Dependent Effects of Cardiac-Specific Overexpression of the A3 Adenosine Receptor Circ. Res., July 26, 2002; 91(2): 165 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Headrick, R. Lasley, E. Kilpatrick, P. Narayan, and R. Mentzer Jr. Apparent Activation of Cardiovascular A1 Adenosine Receptors by A3 Agonists Am J Physiol Heart Circ Physiol, February 1, 2002; 282 (2): H793 - H796. [Full Text] [PDF]
|
|
|
|
|
|
K. Mubagwa and W. Flameng Adenosine, adenosine receptors and myocardial protection: An updated overview Cardiovasc Res, October 1, 2001; 52(1): 25 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zucchi, G. Yu, S. Ghelardoni, F. Ronca, and S. Ronca-Testoni A3 adenosine receptor stimulation modulates sarcoplasmic reticulum Ca2+ release in rat heart Cardiovasc Res, April 1, 2001; 50(1): 56 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. VIRAG and C. SZABO Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death FASEB J, January 1, 2001; 15(1): 99 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. SAURIN, J. L. MARTIN, R. J. HEADS, C. FOLEY, J. W. MOCKRIDGE, M. J. WRIGHT, Y. WANG, and M. S. MARBER The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes FASEB J, November 1, 2000; 14(14): 2237 - 2246. [Abstract] [Full Text]
|
|
|
|
|
|
M. PARSONS, L. YOUNG, J. E. LEE, K. A. JACOBSON, and B. T. LIANG Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D FASEB J, July 1, 2000; 14(10): 1423 - 1431. [Abstract] [Full Text]
|
|
|
|
|
|
M. S. Marber Ischemic Preconditioning in Isolated Cells Circ. Res., May 12, 2000; 86(9): 926 - 931. [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Wellner-Kienitz, K. Bender, T. Meyer, M. Bunemann, and L. Pott Overexpressed A1 Adenosine Receptors Reduce Activation of Acetylcholine-Sensitive K+ Current by Native Muscarinic M2 Receptors in Rat Atrial Myocytes Circ. Res., March 31, 2000; 86(6): 643 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Palmer and G. L. Stiles Identification of Threonine Residues Controlling the Agonist-Dependent Phosphorylation and Desensitization of the Rat A3 Adenosine Receptor Mol. Pharmacol., March 1, 2000; 57(3): 539 - 545. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. A. Jacobson, R. Xie, L. Young, L. Chang, and B. T. Liang A Novel Pharmacological Approach to Treating Cardiac Ischemia. BINARY CONJUGATES OF A1 AND A3 ADENOSINE RECEPTOR AGONISTS J. Biol. Chem., September 22, 2000; 275(39): 30272 - 30279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Pucar, E. Janssen, P. P. Dzeja, N. Juranic, S. Macura, B. Wieringa, and A. Terzic Compromised Energetics in the Adenylate Kinase AK1 Gene Knockout Heart under Metabolic Stress J. Biol. Chem., December 22, 2000; 275(52): 41424 - 41429. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
